Cargando…

Identification of a founder BRCA2 mutation in Sardinia

Sardinian population can be instrumental in defining the molecular basis of cancer, using the identity-by-descent method. We selected seven Sardinian breast cancer families originating from the northern-central part of the island with multiple affected members in different generations. We genotyped...

Descripción completa

Detalles Bibliográficos
Autores principales: Pisano, M, Cossu, A, Persico, I, Palmieri, G, Angius, A, Casu, G, Palomba, G, Sarobba, M G, Rocca, P C Ossu, Dedola, M F, Olmeo, N, Pasca, A, Budroni, M, Marras, V, Pisano, A, Farris, A, Massarelli, G, Pirastu, M, Tanda, Francesco
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2000
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363305/
https://www.ncbi.nlm.nih.gov/pubmed/10682665
http://dx.doi.org/10.1054/bjoc.1999.0963
_version_ 1782153670793625600
author Pisano, M
Cossu, A
Persico, I
Palmieri, G
Angius, A
Casu, G
Palomba, G
Sarobba, M G
Rocca, P C Ossu
Dedola, M F
Olmeo, N
Pasca, A
Budroni, M
Marras, V
Pisano, A
Farris, A
Massarelli, G
Pirastu, M
Tanda, Francesco
author_facet Pisano, M
Cossu, A
Persico, I
Palmieri, G
Angius, A
Casu, G
Palomba, G
Sarobba, M G
Rocca, P C Ossu
Dedola, M F
Olmeo, N
Pasca, A
Budroni, M
Marras, V
Pisano, A
Farris, A
Massarelli, G
Pirastu, M
Tanda, Francesco
author_sort Pisano, M
collection PubMed
description Sardinian population can be instrumental in defining the molecular basis of cancer, using the identity-by-descent method. We selected seven Sardinian breast cancer families originating from the northern-central part of the island with multiple affected members in different generations. We genotyped 106 members of the seven families and 20 control nuclear families with markers flanking BRCA2 locus at 13q12–q13. The detection of a common haplotype shared by four out of seven families (60%) suggests the presence of a founder BRCA2 mutation. Direct sequencing of BRCA2 coding exons of patients carrying the shared haplotype, allowed the identification of a ‘frame-shift’ mutation at codon 2867 (8765delAG), causing a premature termination-codon. This mutation was found in breast cancer patients as well as one prostate and one bladder cancer patient with shared haplotype. We then investigated the frequency of 8765delAG in the Sardinian breast cancer population by analysing 270 paraffin-embedded normal tissue samples from breast cancer patients. Five patients (1.7%) were found to be positive for the 8765delAG mutation. Discovery of a founder mutation in Sardinia through the identity-by-descent method demonstrates that this approach can be applied successfully to find mutations either for breast cancer or for other types of tumours. © 2000 Cancer Research Campaign
format Text
id pubmed-2363305
institution National Center for Biotechnology Information
language English
publishDate 2000
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23633052009-09-10 Identification of a founder BRCA2 mutation in Sardinia Pisano, M Cossu, A Persico, I Palmieri, G Angius, A Casu, G Palomba, G Sarobba, M G Rocca, P C Ossu Dedola, M F Olmeo, N Pasca, A Budroni, M Marras, V Pisano, A Farris, A Massarelli, G Pirastu, M Tanda, Francesco Br J Cancer Regular Article Sardinian population can be instrumental in defining the molecular basis of cancer, using the identity-by-descent method. We selected seven Sardinian breast cancer families originating from the northern-central part of the island with multiple affected members in different generations. We genotyped 106 members of the seven families and 20 control nuclear families with markers flanking BRCA2 locus at 13q12–q13. The detection of a common haplotype shared by four out of seven families (60%) suggests the presence of a founder BRCA2 mutation. Direct sequencing of BRCA2 coding exons of patients carrying the shared haplotype, allowed the identification of a ‘frame-shift’ mutation at codon 2867 (8765delAG), causing a premature termination-codon. This mutation was found in breast cancer patients as well as one prostate and one bladder cancer patient with shared haplotype. We then investigated the frequency of 8765delAG in the Sardinian breast cancer population by analysing 270 paraffin-embedded normal tissue samples from breast cancer patients. Five patients (1.7%) were found to be positive for the 8765delAG mutation. Discovery of a founder mutation in Sardinia through the identity-by-descent method demonstrates that this approach can be applied successfully to find mutations either for breast cancer or for other types of tumours. © 2000 Cancer Research Campaign Nature Publishing Group 2000-02 2000-01-18 /pmc/articles/PMC2363305/ /pubmed/10682665 http://dx.doi.org/10.1054/bjoc.1999.0963 Text en Copyright © 2000 Cancer Research Campaign https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Regular Article
Pisano, M
Cossu, A
Persico, I
Palmieri, G
Angius, A
Casu, G
Palomba, G
Sarobba, M G
Rocca, P C Ossu
Dedola, M F
Olmeo, N
Pasca, A
Budroni, M
Marras, V
Pisano, A
Farris, A
Massarelli, G
Pirastu, M
Tanda, Francesco
Identification of a founder BRCA2 mutation in Sardinia
title Identification of a founder BRCA2 mutation in Sardinia
title_full Identification of a founder BRCA2 mutation in Sardinia
title_fullStr Identification of a founder BRCA2 mutation in Sardinia
title_full_unstemmed Identification of a founder BRCA2 mutation in Sardinia
title_short Identification of a founder BRCA2 mutation in Sardinia
title_sort identification of a founder brca2 mutation in sardinia
topic Regular Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2363305/
https://www.ncbi.nlm.nih.gov/pubmed/10682665
http://dx.doi.org/10.1054/bjoc.1999.0963
work_keys_str_mv AT pisanom identificationofafounderbrca2mutationinsardinia
AT cossua identificationofafounderbrca2mutationinsardinia
AT persicoi identificationofafounderbrca2mutationinsardinia
AT palmierig identificationofafounderbrca2mutationinsardinia
AT angiusa identificationofafounderbrca2mutationinsardinia
AT casug identificationofafounderbrca2mutationinsardinia
AT palombag identificationofafounderbrca2mutationinsardinia
AT sarobbamg identificationofafounderbrca2mutationinsardinia
AT roccapcossu identificationofafounderbrca2mutationinsardinia
AT dedolamf identificationofafounderbrca2mutationinsardinia
AT olmeon identificationofafounderbrca2mutationinsardinia
AT pascaa identificationofafounderbrca2mutationinsardinia
AT budronim identificationofafounderbrca2mutationinsardinia
AT marrasv identificationofafounderbrca2mutationinsardinia
AT pisanoa identificationofafounderbrca2mutationinsardinia
AT farrisa identificationofafounderbrca2mutationinsardinia
AT massarellig identificationofafounderbrca2mutationinsardinia
AT pirastum identificationofafounderbrca2mutationinsardinia
AT tandafrancesco identificationofafounderbrca2mutationinsardinia